Effectiveness of Bosentan VS Sildenafil for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Autor: Dr. Galiba Tasnim, Dr. Wahida Khanam, Dr. Shahana Begum, Dr. Umme Saima Hossain, Dr. Tanjina Sharifa, Dr. Md. Moshiur Rahman Mia, Dr. Rubiya Parvin, Dr. Md. Mozibur Rahman
Rok vydání: 2021
Předmět:
Zdroj: Scholars Journal of Applied Medical Sciences. 11:560-567
ISSN: 2320-6691
2347-954X
Popis: Background: Persistent pulmonary hypertension of the newborn (PPHN) is a serious disease among newborns. Pulmonary vasodilators such as Sildenafil, Bosentan and Milrinone are important treatment modalities to treat persistent pulmonary hypertension of the newborn, especially in resource limited centers where inhaled nitric oxide is not available. Objective: To assess and compare the effectiveness of Bosentan and Sildenafil in persistent pulmonary hypertension of the newborn. Method: This randomized controlled trial was done in the NICU, ICMH, Matuail, Dhaka during July 2017 to July 2019. Following echocardiographic diagnosis, a total of 76 patients were randomly assigned into group A and group B (by lottery). Bosentan was given to group A (1mg/kg/body wt) 12 hourly for 7 days and Sildenafil was given to group B (2mg/kg/body wt.) 8 hourly for 7 days via oro-gastric tube/orally. Then heart rate, respiratory rate, cyanotic changes, SPO2 was recorded every day for 7 days and finally on the 8th day echocardiographic findings were obtained. Effects of two groups were compared. Results: The age of presentation of persistent pulmonary hypertension of newborn was < 24 hours and male newborns were predominant in both groups. Almost 100 % newborns had cyanosis, tachypnea and SPO2 0.05) difference. The mean length of stay in hospital was 13.05 ± 2.96 days for group A and 13.34 ± 2.86 days for group B. The mean length of ......
Databáze: OpenAIRE